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Background
Soluble guanylate cyclase (sGC) stimulators are small
molecule agonists of sGC that are heme-dependent, nitric
oxide (NO)-independent, and act in synergy with NO.
Herein, we describe a novel class of pyrazole-pyrimidine
sGC stimulators and their evolution from an early lead to
IWP-051 by optimizing SAR for in vitro potency, pharma-
cokinetic parameters, and off-target activity.
Conclusion
IWP-051 is a potent sGC stimulator with >99% plasma
protein binding, high metabolic stability, high perme-
ability, and no efflux in a Caco-2 model of intestinal
absorption. In rat PK studies, IWP-051 had low clear-
ance and a low volume of distribution. Its elimination
half-life in rats was >4 hrs. IWP-051 exhibited dose-
related oral exposure, its Tmax was >3 hrs in rats, and
its oral bioavailability was >40% in mice, rats, and dogs.
In normotensive rats, oral doses of IWP-051 ranging
from 1 to 100 mg/kg decreased mean arterial pressure
in a sustained and dose-responsive manner. Distinct fea-
tures of the pharmacologic profile of IWP-051, including
metabolic stability, protracted gastrointestinal absorp-
tion, and sustained effect on hemodynamics upon oral
dosing in rats, make IWP-051 an exciting pharmacologic
advancement in the sGC stimulator class.
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